SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that
Amit Munshi, the Company's President
and Chief Executive Officer will present a corporate update at the
35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 9:00am PT. The conference will take place
January 9-12, 2017, at the Westin St.
Francis in San Francisco, CA.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event. Please connect to Arena's website
several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
We are a
biopharmaceutical company focused on developing novel, small
molecule drugs across a range of therapeutic areas. We have
three primary proprietary investigational clinical programs:
etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis,
APD371 entering Phase 2 evaluation for the treatment of pain
associated with Crohn's disease, and ralinepag (APD811) in Phase 2
evaluation for pulmonary arterial hypertension
(PAH). Additionally, we have collaborations with the following
pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; and Arena's focus,
primary programs and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.210.3636
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300377009.html
SOURCE Arena Pharmaceuticals, Inc.